High frequency of co-resistance in CTX-M-producing Escherichia coli to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 4, 2013, Pages 271-278

  Balkhed, Åse Östholm ^a   Tärnberg, Maria ^a   Monstein, Hans Jürg ^a   Hällgren, Anita ^a   Hanberger, Håkan ^a   Nilsson, Lennart E ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Etest; Extended spectrum beta lactamase; Minimum inhibitory concentration

Indexed keywords

AMIKACIN; BETA LACTAMASE CTX M; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; NALIDIXIC ACID; NITROFURANTOIN; QUINOLONE; TIGECYCLINE; TOBRAMYCIN; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; ESCHERICHIA COLI; GENOTYPE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; SWEDEN;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; STATISTICS, NONPARAMETRIC; SWEDEN;

EID: 84875435636     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.734636     Document Type: Article

References (56)

1. Drieux L, Brossier F, Sougakoff W, Jarlier V. P henotypic detection of extended-spectrum beta-lactamase productionin Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 2008 ; 14(Suppl 1) : 90-103.
2. Pitout JD, Laupland KB. E xtended-spectrum betalactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008 ; 8 : 159-66.
3. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007 ; 59 : 165-74.
4. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, et al. Prevalence and spread of extendedspectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008 ; 14(Suppl 1) : 144-53.
5. Coque TM, Baquero F, Canton R. I ncreasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008 ; 13. pii: 19044.
6. Bush K, Jacoby G. Lactamase classifi cation and amino acid sequences for TEM, SHV. and OXA extendedspectrum. and inhibitor resistant enzymes. Lahey Clinic; 2012. Available at : http://www.lahey.org/Studies/(accessed 24 September 2012).
7. Alsterlund R, Carlsson B, Gezelius L, Haeggman S, Olsson-Liljequist B. Multiresistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak. Scand J Infect Dis 2009 ; 41 : 410-5.
8. Naseer U, Haldorsen B, Tofteland S, Hegstad K, Scheutz F, Simonsen GS, et al. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009 ; 117 : 526-36.
9. Bonnedahl J, Drobni P, Johansson A, Hernandez J, Melhus Å, Stedt J, et al. Characterization, and comparison, of human clinical and black-headed gull (Larus ridibundus) extendedspectrum beta-lactamase-producing bacterial isolates from Kalmar, on the southeast coast of Sweden. J Antimicrob Chemother 2010 ; 65 : 1939-44.
10. Ös tholm-Balkhed A, Tär nberg M, Nilsson M, Johansson AV, Hanberger H, Monstein HJ, et al. Prevalence of extendedspectrum beta-lactamase-producing Enterobacteriaceae and trends in antibiotic consumption in a county of Sweden. Scand J Infect Dis 2010 ; 42 : 831-8.
11. Stromdahl H, Tham J, Melander E, Walder M, Edquist P J, Odenholt I. Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of southern Sweden. Eur J Clin Microbiol Infect Dis 2011 ; 30 : 1159-62.
12. Morosini MI, Garcia-Castillo M, Coque T M, Valverde A, Novais A, Loza E, et al. Antibiotic coresistance in extendedspectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006 ; 50 : 2695-9.
13. Rodriguez-Bano J, Navarro M D, Romero L, Muniain M A, de Cueto M, Rios MJ, et al. Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006 ; 43 : 1407-14.
14. Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibioticresistant strain and their impact on the outcome. J Antimicrob Chemother 2009 ; 63 : 568-74.
15. Cavaco L M, Hansen D S, Friis-Moller A, Aarestrup F M, Hasman H, Frimodt-Moller N. First detection of plasmid-mediated quinolone resistance (qnrA and qnrS) in Escherichia coli strains isolated from humans in Scandinavia. J Antimicrob Chemother 2007 ; 59 : 804-5.
16. Cavaco L M, Hendriksen R S, Aarestrup F M. P lasmidmediated quinolone resistance determinant qnrS1 detectedin Salmonella enterica serovar Corvallis strains isolated in Denmark and Thailand. J Antimicrob Chemother 2007 ; 60 : 704-6.
17. M, Hammerum A M, Zachariasen C, Nielsen EM. Detection of qnr genes in Salmonella isolated from humans in Denmark. J Antimicrob Chemother 2009 ; 63 : 406-8.
18. Fang H, Huang H, Shi Y, Hedin G, Nord C E, Ullberg M. Prevalence of qnr determinants among extended-spectrum beta-lactamase-positive Enterobacteriaceae clinical isolates in southern Stockholm, Sweden. Int J Antimicrob Agents 2009 ; 34 : 268-70.
19. Gunell M, Webber MA, Kotilainen P, Lilly AJ, Caddick JM, Jalava J, et al. Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. Antimicrob Agents Chemother 2009 ; 53 : 3832-6.
20. Karah N, Poirel L, Bengtsson S, Sundqvist M, Kahlmeter G, Nordmann P, et al. Plasmid-mediated quinolone resistance determinants qnr and aac(6 -)-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden. Diagn Microbiol Infect Dis 2010 ; 66 : 425-31.
21. Strahilevitz J, Jacoby G A, Hooper D C, Robicsek A. P lasmidmediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009 ; 22 : 664-89.
22. Rodriguez-Martinez JM, Cano ME, Velasco C, Martinez-Martinez L, Pascual A. Plasmid-mediated quinolone resistance: an update. J Infect Chemother 2011 ; 17 : 149-82.
23. T är nberg M, Ös tholm-Balkhed A, Monstein HJ, Hä l lgren A, Hanberger H, Nilsson LE. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2011 ; 30 : 981-7.
24. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, v. 1.3. EUCAST ; 2011. Available at : http://www. eucast.org/fi leadmin/src/media/PDFs/EUCAST-fi les/Disk-test-documents/EUCAST-breakpoints-v1.3-pdf.pdf (accessed 24 September 2012).
25. Magiorakos AP, Srinivasan A, Carey R B, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard defi nitions for acquired resistance. Clin Microbiol Infect 2012 ; 18 : 268-81.
26. Lobel B. S hort term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theories. Int J Antimicrob Agents 2003 ; 22(Suppl 2) : 85-7.
27. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007 ; 29 : 62-5.
28. Rodriguez-Bano J, Alcala J C, Cisneros J M, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase- producing Escherichia coli. Arch Intern Med 2008 ; 168 : 1897-902.
29. Falagas ME, Kastoris A C, Kapaskelis A M, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010 ; 10 : 43-50.
30. Auer S, Wojna A, Hell M. O ral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli. Antimicrob Agents Chemother 2010 ; 54 : 4006-8.
31. Falagas ME, Maraki S, Karageorgopoulos D E, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010 ; 35 : 240-3.
32. Liu HY, Lin HC, Lin YC,Y u SH, Wu WH, Lee Y J. A ntimicrobial susceptibilities of urinary extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011 ; 44 : 364-8.
33. Samonis G, Maraki S, Karageorgopoulos D E, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrugresistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012 ; 31 : 695-701.
34. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005 ; 40 : 1333-41.
35. Zavascki AP, Goldani L Z, Li J, Nation R L. P olymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007 ; 60 : 1206-15.
36. Simner P J, Zhanel G G, Pitout J, Tailor F, McCracken M, Mulvey MR, et al. Prevalence and characterization of extendedspectrum beta-lactamase-and AmpC beta-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011 ; 69 : 326-34.
37. Lu CT, Chuang Y C, Sun W, Liu Y C, Cheng Y J, Lu P L, et al. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum betalactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2008 ; 32(Suppl 3) : S179-83.
38. Kelesidis T, Karageorgopoulos D E, Kelesidis I, Falagas M E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008 ; 62 : 895-904.
39. Norskov-Lauritsen N, Marchandin H, Dowzicky M J. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009 ; 34 : 121-30.
40. Sader HS, Farrell D J, Jones R N. T igecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009). Diagn Microbiol Infect Dis 2011 ; 69 : 223-7.
41. Silva-Sanchez J, Reyna-Flores F, Velazquez-Meza M E, Rojas-Moreno T, Benitez-Diaz A, Sanchez-Perez A. In vitro activity of tigecycline against extended-spectrum beta-lactamaseproducing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study. Diagn Microbiol Infect Dis 2011 ; 70 : 270-3.
42. Fraise A P. T igecycline: the answer to beta-lactam and fl uoroquinolone resistance? J Infect 2006 ; 53 : 293-300.
43. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen A B, Furuya EY, Wilson SJ, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011 ; 55 : 5893-9.
44. Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, Orden B, et al. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 2006 ; 44 : 2359-66.
45. Rodriguez-Villalobos H, Malaviolle V, Frankard J, de Mendonca R, Nonhoff C, Struelens MJ. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 2006 ; 57 : 771-4.
46. Pitout JD, Le P, Church DL, Gregson DB, Laupland KB. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/ tazobactam. Int J Antimicrob Agents 2008 ; 32 : 333-8.
47. Cavaco L M, Frimodt-Moller N, Hasman H, Guardabassi L, Nielsen L, Aarestrup FM. Prevalence of quinolone resistance mechanisms and associations to minimum inhibitory concentrations in quinolone-resistant Escherichia coli isolated from humans and swine in Denmark. Microb Drug Resist 2008 ; 14 : 163-9.
48. Ramirez MS, Tolmasky M E. A minoglycoside modifying enzymes. Drug Resist Updat 2010 ; 13 : 151-71.
49. Christiansen N, Nielsen L, Jakobsen L, Stegger M, Hansen LH, Frimodt-Moller N. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fl uoroquinolone consumption in a low-use country. Microb Drug Resist 2011 ; 17 : 395-406.
50. Lindemann PC, Risberg K, Wiker HG, Mylvaganam H. Aminoglycoside resistance in clinical Escherichia coli and Klebsiella pneumoniae isolates from Western Norway. APMIS 2012 ; 120 : 495-502.
51. European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of microorganisms. EUCAST ;. Available at : http://mic.eucast.org/Eucast2/(accessed 24 September 2012).
52. Puerto A S, Fernandez JG, del Castillo Jde D, Pino MJ, Angulo GP. In vitro activity of beta-lactam and non-betalactam antibiotics in extended-spectrum beta-lactamaseproducing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 2006 ; 54 : 135-9.
53. Lagace-Wiens PR, Nichol KA, Nicolle LE, Decorby MR, McCracken M, Alfa MJ, et al. ESBL genotypes in fl uoroquinolone-resistant and fl uoroquinolone- susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba. Can J Infect Dis Med Microbiol 2007 ; 18 : 133-7.
54. Tofteland S, Haldorsen B, Dahl K H, Simonsen GS, Steinbakk M, Walsh TR, et al. Effects of phenotype and genotype on methods for detection of extended-spectrumbeta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007 ; 45 : 199-205.
55. Queenan AM, Bush K. C arbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007 ; 20 : 440-58.
56. Kumarasamy KK, Toleman MA, Walsh T R, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010 ; 10 : 597-602.